Both ENLIST training cell lines are required to fully induce and expand high numbers of tumor killing SUPLEXA cells from PBMCs.
Importantly, ENLIST cells can be rendered non-viable using repeated freeze thawing or lyophilization and still yield SUPLEXA therapeutic cells with similar potency as using live ENLIST cells. Using inactivated ENLIST cells adds another layer of safety in that patients are never exposed to living tumor derived ENLIST cells. The analytic assessment of SUPLEXA therapeutic cells using CyTOF, and measures of cytolytic activity, and cytokine profiles indicate that the manufacturing process is robust and consistently results in potent tumor killing effector cells.